Avexegen Therapeutics is organized around working on novel breakthrough therapies for diseases with unmet needs beginning with the firm's first-in-class drug candidate, neuregulin-4, targeting treatment of GI disorders including Crohn's, ulcerative colitis and necrotizing enterocolitis, the latter a rare disease which afflicts premature infants. The firm's lead compound, Neuregulin-4, has been developed in collaboration with Children's Hospital Los Angeles.
